| Abstrakt: |
A recent study conducted at Hiroshima University in Japan analyzed the genetic profiles of Japanese castration-resistant prostate cancer patients using comprehensive genomic profiling testing. The study found that androgen-receptor alteration was the most frequently detected genetic alteration, followed by TP53, CDK12, phosphatase and tensin homolog, and ATM mutations. The researchers also discovered that patients who received systemic therapy based on the comprehensive genomic profiling testing had a significantly higher survival rate compared to those who did not receive new therapeutic treatment. The study concludes that comprehensive genomic profiling testing is recommended for castration-resistant prostate cancer patients as it can provide new therapeutic options. [Extracted from the article] |
